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Split-Course Palliative Radiotherapy for Advanced
Non-small Cell Lung Cancer
Su K. Metcalfe, MD, MPH, Michael T. Milano, MD, PhD, Kevin Bylund, MD, Therese Smudzin, BS,
Philip Rubin, MD, and Yuhchyau Chen, MD, PhD
Purpose: Palliative chest radiotherapy (RT) for lung malignancies is
effective in relieving serious chest symptoms from tumor bleeding
or mass effect on major airways, vessels, and nerves. Albeit an
important subject, there is a lack of consensus for an optimal
palliative RT regimen. We report the outcomes of a split-course
palliative chest RT, a frequently used schema at our institution.
Methods and Materials: Records of 140 patients treated between
1995 and 2006 were reviewed. Treatment was prescribed to an
initial 25 Gy in 10 fractions through anterior-posterior/posterior-
anterior beam arrangements. After a 2-week rest period, patients
were selected to receive an additional 10 Gy (anterior-posterior/
posterior-anterior) followed by off-cord beams to a final dose of 50
to 62.5 Gy. Symptom relief and toxicity during RT and after
completion of RT were assessed from clinician notes and patient-
reported symptom inventory forms. Second, the impact on survival
was assessed.
Results: Symptomatic relief was observed in 52 to 84% of patients
with durable palliation in 58%. There were no grade 3 to 5 toxicities.
Grades 1 and 2 esophagitis and pneumonitis were observed in 34
and 8% patients, respectively. Median survival was 5 months.
Conclusions: A majority of patients experienced symptomatic im-
provement. The built-in 2-week break allowed for selection of
patients for high-dose palliative radiation and balanced treatment
benefits with potential side effects. Cancer survival was not ad-
versely affected by treatments in this population with mostly ad-
vanced disease. This regimen is a viable option for patients who
cannot tolerate a protracted, uninterrupted course of treatment.
Key Words: Lung cancer, Palliation, Radiation, Split course,
Hypofractionation.
(J Thorac Oncol. 2010;5: 185–190)
Lung cancer remains the most common cause of cancer-related mortality in the United States.1 The majority of
patients present with locally advanced or stage IV disease, and
the survival for these patients is dismal, despite aggressive
treatments.1 Tumor bleeding can cause fatal hemoptysis, and the
mass effect of tumor in the thorax can cause symptoms such as
cough, shortness of breath, chest pain, cardiac arrhythmia,
esophageal obstruction, brachial plexopathy, superior vena cava
compression, airway obstruction, or postobstructive pneumonia.
The primary challenge in treating patients with advanced lung
cancer is that most patients present with poor performance status
or significant comorbidities, and the benefit of treatment may be
doubtful because of poor tolerance to any form of therapy.
However, palliative radiotherapy (RT) continues to be an im-
portant modality and a common practice in the management of
patients with chest symptoms and who cannot undergo intensive
therapy.
Although palliative RT plays a significant role in the
management of advanced lung cancer, there is no clear consen-
sus regarding the optimal dose or fractionation schedule. In a
phase III randomized trial, the United Kingdom’s Medical Re-
search Council reported equivalent palliation with hypofraction-
ated RT given in two 8.5 Gy fractions versus 30 Gy in 10
fractions, or when comparing two large 8.5 Gy fractions with a
single fraction of 10 Gy.2,3 This approach has not been univer-
sally accepted because of a concern of increased toxicity from
such large fractions, although the evidence for this is rather
limited and these reports were studied in different patient pop-
ulations.4 Although such abbreviated treatment schedules may
be suitable for patients with significant comorbidities or ex-
tremely poor prognosis from advanced disease, some literature
suggests that protracted hypofractionated RT to higher total
doses in patients with good performance status (Zubrod 0 or 1)
may result in some survival benefit. The Dutch National Study
and a National Cancer Institute of Canada study both reported
comparable symptom control and noted a survival advantage in
favor of protracted hypofractionated RT in the subgroup with
better prognoses.4,5 Moreover, the duration of symptom relief
was prolonged using protracted regimens. Conversely, a large
Norwegian study showed no difference in symptom control or
survival by three different fractionation schedules.6 Although the
correlation between higher RT dose in alleviating symptoms and
in improving survival has been controversial, the potential ben-
efits of higher total dose RT are supported by a recent meta-
analysis of 13 randomized clinical trials evaluating palliative
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thoracic RT regimens. This study reported statistically improved
total symptom score and overall survival (OS) at 2 years with
higher doses of RT of at least 35 Gy10 BED when compared
with lower total dose and larger fraction sizes.7 A critical
question remains in the selection of appropriate lung cancer
patients for high-dose palliative RT, given the overall poor
prognosis of this patient population.
In the past decade, a selection design, split-course hypo-
fractionated RT schedule has been the most frequently used
schema for palliative chest RT of lung cancer at the University
of Rochester Medical Center. The rationale is that the first
course of 25 Gy given in 2.5 Gy daily fractions serves as a trial
course for assessing treatment tolerance in this challenging
patient population. This would be followed by a planned 2-week
break to select those patients who have tolerated their initial
treatment and to allow for recovery from RT-induced acute
fatigue and potential esophagitis from the first course. Although
a minority of patients would deteriorate from either disease
progression or intolerance to therapy during the break, patients
who felt better and stronger would resume RT to complete the
second course of RT in 2.5 Gy fractions to the final total dose of
50 to 62.5 Gy. Therefore, this selection design allows identifi-
cation of patients who may tolerate high-dose palliative RT after
an initial trial dose. In our experience, this approach has been
well tolerated, and most patients benefited from improvement of
chest symptoms while allowing all patients a chance to receive
the trial course of palliative RT. We sought to assess the overall
efficacy of this split-course palliative radiation regimen for
symptom relief and to analyze any impact on survival by
conducting a retrospective review.
PATIENTS AND METHODS
Patient Population
This retrospective chart review study was approved by
the Institutional Review Board of University of Rochester.
We reviewed medical records and RT records of all patients
treated with split-course thoracic RT for lung cancer between
1995 and 2006 in the Department of Radiation Oncology. We
identified a total of 140 patients with non-small cell lung
cancer (NSCLC) who received this treatment by reviewing
the department’s disease-specific treatment lists. These pa-
tients were not candidates for curative RT because of signif-
icant comorbidities, poor performance status, metastatic dis-
ease, or malignant pleural effusion.
Treatment
All patients were initially planned to receive the
split-course palliative RT. Treatment was prescribed to a
course of 25 Gy in 10 fractions through anterior-posterior/
posterior-anterior beam arrangements. After this first course
of RT, patients received a 2-week break, after which time
patients and physician jointly determined whether any patient
would proceed to the second course of RT. The criteria used to
select patients for the second course of RT were adequate
performance status, patient’s willingness to proceed, stable dis-
ease status of treated tumor, and no distant progression. The
second course consisted of an additional 10 Gy in four fractions,
anterior-posterior/posterior-anterior, followed by 15 to 22.5 Gy
in six to nine fractions for a total of 50 to 62.5 Gy using oblique
or computed tomography-based conformal off-cord beam ar-
rangements. Patients with larger initial tumor volumes (usually
5 cm) who tolerated treatment up to 50 Gy and those with
localized diseases were given higher overall doses (62.5 Gy)
with the intent to confer better local control and a more sustained
palliative response. Total spinal cord dose did not exceed 40 Gy.
Analyses
Symptom Palliation
Symptom improvement was based on clinician assess-
ments at weekly treatment evaluations during RT, from clinic
follow-up notes, as well as data from University of Rochester
oncology symptom inventory forms for more recently treated
patients since 2003, which comprised 9% of total patients.
The symptom inventory forms were given at the time of
weekly on-treatment visits, and patients were requested to
complete these forms before their weekly evaluations with
their radiation oncologists. If discrepancies were noted from
clinician assessments and patient-completed surveys, the pa-
tient survey answers were documented for this analysis.
Toxicities
Toxicities were graded retrospectively from clinician
notes during the weekly treatment evaluations, during routine
follow-up appointments in the months after completion of RT
and the University of Rochester oncology symptom inventory
forms. The worst toxicity documented either during RT or
assessed retrospectively was scored using the Common Ter-
minology Criteria for Adverse Events v3.0 scale.8 To apply
consistent criteria in assigning toxicity scores, only one
clinician extracted these data for the entire group, thereby
attempting to minimize interobserver variation. Then, a pro-
portion of these charts were selected randomly and evaluated
by a senior physician to confirm the patients’ toxicity score.
Any differences in scoring were resolved by re-reviewing the
patients’ clinic chart, and the senior physician made the final
determination.
Survival
Survival statistics were measured from the start date of
RT to the time of last follow-up or when death was docu-
mented. The Kaplan-Meier survival was estimated at 6
months, 1, and 2 years.9 Significant variables on univariate
analyses (UVA) were tested with multivariate analyses
(MVA). MVA were performed with the Cox proportional
hazards regression model.10 All p values were two sided, and
values 0.05 were considered significant. STATA version
9.2 was used for all data analyses.
RESULTS
Patient Characteristics
Patient and disease characteristics are summarized in Ta-
ble 1. Fifty-seven percent of the patients had stage IV or IIIB
NSCLC with a malignant pleural effusion (“wet IIIB”). Eighty-
eight percent (n 123) of patients completed the first course of
RT, and 116 of these patients (94%) were selected to begin
course 2 RT. Of the 116 patients who proceeded with course 2,
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87% completed the entire course of treatment to a total of 50 to
62.5 Gy. In all, 101 of the 140 patients completed both courses
of RT. Reasons for stopping treatment before completing the full
course included patient death from progressive disease (n 11),
patient’s decision to discontinue further oncologic treatment
(n 19), physician’s recommendation to halt treatment because
of deteriorating health or poor tolerance to therapy (n  8), or
other reasons (n  1).
Four of the 140 patients were previously irradiated to the
lung, and the current course of palliative split-course RT for
these patients was delivered through an off-cord arrangement
through the entire treatment. Twenty-eight patients received
chemotherapy at some time during their cancer management. Of
these, 14 patients received chemotherapy before RT, nine re-
ceived chemotherapy after RT, three received chemotherapy
before and after RT, and two patients received concurrent
treatment. Thirteen patients underwent surgery for their lung
cancer previously, and these patients received RT for recurrent
thoracic disease rather than for adjuvant treatment.
Symptom Palliation
Symptomatic improvement was assessed in all patients
from weekly notes of on-treatment evaluation and from the
follow-up notes until the last follow-up or until death with a
median follow-up of 5 months. Table 2 showed that 52% to
84% of patients had various symptomatic improvements after
completing the full course of palliative RT. Of note, with the
exception of patients who presented with hemoptysis, 35%
described symptom relief at the end of the first treatment
course (25 Gy). The remaining patients reported palliation
from shortness of breath, cough, and chest pain between 35
and 62.5 Gy. Hemoptysis resolved after an average of 10 Gy.
Durable symptom relief, defined as continued symptom pal-
liation evaluated on subsequent follow-up, was observed in
58% of patients evaluated during follow-up visits.
Toxicity
There were no grade 4 or 5 RT side effects. Grade 3
esophagitis and pneumonitis were observed in 2% of patients.
Grades 1 and 2 esophagitis and pneumonitis were seen in 34
and 8%, respectively. In all patients, mild esophagitis from
the first course of RT resolved during the 2-week break
period (Table 3).
Survival
The OS curve is depicted in Figure 1. The median OS was
5.0 months for all patients. The 6-month, 1-year, and 2-year OS
are 45, 26, and 15%, respectively. Among the 86 patients with
stage IV or wet stage IIIB disease, the median OS was 4.1
months (Figure 2). The patients who completed the entire course
of RT had a median OS of 6.5 months; OS was 1.2 months for
those who did not complete the first course or did not proceed to
the second course after the 2-week break 2  47.19 (p 
0.0001) (Figure 3).
On UVA and MVA for survival outcome, patients with
poor Karnofsky Performance Status score and weight loss had
TABLE 1. Patient and Disease Characteristics
Demographics
Number (%),
N  140 (100%)
Sex
Male 86 (61)
Female 54 (39)
Age
Median 68
Range 35–92
KPS
90–100 34 (24)
70–80 73 (53)
60 33 (23)
Weight loss 5% of body weight
Yes 80 (57)
No 38 (27)
Unknown 22 (16)
Stage
I–IIB 13 (9)
IIIA and IIIB (no pleural effusion) 41 (29)
IIIB with malignant pleural effusion 12 (9)
IV 74 (53)
Histology
Adenocarcinoma 63 (45)
Squamous cell carcinoma 47 (34)
Other NSCLC or unknown 30 (21)
Chemotherapy
Prior 14 (10)
After 9 (6)
Prior and after 3 (2)
Concurrent 2 (1)
Prior lung surgery
Yes 13 (9)
No 127 (91)
Radiation treatment
Completed course 1  25 Gy 123 (88)
Completed entire course 50 Gy 101 (72)
NSCLC, non-small cell lung cancer; KPS, Karnofsky performance status score.
TABLE 2. Palliation of Symptoms in Evaluable Patients
Symptom
Patients with
Symptoms at
Presentation
Patients with
Symptom
Improvementa
Shortness of breath 90 (64) 53 (59)
Cough 98 (70) 51 (52)
Hemoptysis 25 (18) 21 (84)
Chest pain 41 (29) 34 (83)
Anorexia 55 (39) 39 (71)
All the values are given in n (%).
a Only includes patients who had symptoms at presentation.
TABLE 3. Treatment Toxicity by CTCAE v.3.0
Grade 1 Grade 2 Grade 3 Grades 4 and 5
Esophagitis (%) 34 8 2 0
Pneumonitis (%) 34 8 2 0
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significantly worse survival. Stage was significant on UVA, and
we assessed the survival for patients with wet stage IIIB or IV
NSCLC compared with other stages (Figure 2). This analysis
showed a borderline significant trend toward worse survival on
UVA (4.1 versus 5.9 months, p 0.052) andMVA (p 0.062).
Age was not significant on UVA or MVA for survival (Table 4).
DISCUSSION
Radiation remains an effective and a commonly used
local therapy to relieve thoracic symptoms for lung cancers of
all stages.11 Review of the literature shows that different dose
fractionation schedules have been formally tested, yet there is
wide heterogeneity globally in the RT dose and fraction size
prescribed for palliative chest RT (Table 5). Comparison of
data from these trials has been challenging, given the differ-
ences in patient population (range of performance status, age,
inclusion of small cell lung cancer, methods of symptom
assessment, and measured outcomes). However, the meta-
analysis by Fairchild et al.,7 suggests that a selected group of
patients can be considered for higher total doses of RT to
derive more durable palliation and improved overall survival.
Then, the appropriate selection of patients who may benefit
most from a protracted course of RT is essential in this
population who often have poor performance status or sig-
nificant comorbidities.
Balancing symptomatic relief with RT side effects re-
mains critical in palliative intervention. We propose that our
selection design avoids overtreatment of very ill patients with
resultant toxicities and allows for recovery from the mild esoph-
agitis or fatigue from the first course of RT. This approach
facilitates identification of patients suitable for high-dose RT
after a trial dose of 25 Gy. Only patients who did not deteriorate
after the 2-week break proceeded with further RT.
Certainly, data from a retrospective review of clinical
information did not allow an objective comparison of efficacy
given the potential subjectivity, patient selection, and biases
inherent in this type of study design. Nonetheless, our split-
course regimen conferred symptom improvement in 84% of
patients. Therapy was well tolerated, and toxicity was mild
and transient, with grade 1 or 2 esophagitis completely
resolved during the 2-week scheduled break. We observed
that only 2% of patients overall had grade 3 esophagitis
during RT or in the months after completion of treatment.
The low rate and severity of esophagitis are consistent with
the clinical experience using this regimen at our institution.
The planned break may elicit criticism in that extended
duration or interruption of treatment may adversely impact
local tumor control and disease-specific survival, as observed
in patients receiving curative-intent RT for NSCLC.21,22 In
general, assessment of palliative RT regimens has focused on
clinical symptomatic response, and not on local tumor con-
trol, given the short survival and limited chest imaging in
patients treated for palliation. We did not assess local control
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FIGURE 1. Kaplan-Meier estimates of overall survival for all
patients.
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FIGURE 2. Kaplan-Meier estimates of overall survival for
patients with “wet” stage IIIB and IV disease versus other
stages of non-small cell lung cancer (NSCLC).
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FIGURE 3. Kaplan-Meier estimates of overall survival for
patients who completed treatment versus those who did not
complete entire treatment.
TABLE 4. Univariate and Multivariate Analyses for Overall
Survival
Variable Univariate p Value Multivariate p Value
Sex 0.86
Age 0.442
KPS 0.002 0.013
Weight loss 0.0002 0.000
Stage 0.052 0.062
KPS, Karnofsky performance status score.
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TABLE 5. Palliative Radiation Trials for Lung Cancer
Fractionation
Schema N Stage KPS
Median
Survival (mo)
1-yr
Survival (%) Response Complications Reference
50 Gy/20 F 140 Inoperable Any 5 26 52–84% symptom
improvement
None; mild
esophagitis and
pneumonitis
Current series
0 6.5a
30 Gy/10 F 369 Inoperable Any 5.9 23 Equally effective Radiation myelopathy
in 1 pt
MRC I2
17 Gy/2 F (Includes
M)
6.0 20
17 Gy/2 F 235 Inoperable WHO 2–4 3.3 14 1F slightly better for all
except hemoptysis
2F w/more dysphagia MRC II3
10 Gy/1 F (Includes
M)
4.0 9
20 Gy/5 F 230 Inoperable WHO 0–3 6 NR Symptom control
equivalent
Toxicity similar Bezjak et al.4
10 Gy/1 F (Includes
M)
4.2, p  0.031
16 Gy/2 F 297 IIIA–IV WHO 3–4 or
0–2 for IV
n/a 11 Symptom control
equivalent but
prolonged palliation
w/10 F
Toxicity similar Kramer et al.5
30 Gy/10 F (Includes
M)
n/a 20, p  0.03
17 Gy/2 F 421 IIIA–IV
(includes
M)
Any 8.2 29 Symptom control
equivalent
Reduced physical and
social functioning
w/shorter tx; earlier
dysphagia
w/shorter tx
Sundstrom et al.6
42 Gy/15 F 7 29
50 Gy/25 F 6.8, p  0.83 31
10 Gy/1 F 149 Inoperable
(includes
SCLC)
WHO 0–3 5.7 19 23% w/symptom
resolution for
fractionated; 5%
w/single fraction
Toxicity similar Erridge et al.12
30 Gy/10 F 7.1, p  0.197 28
45 Gy/18 F 273 Inoperable Any 5 NR 18 F higher response
rate; duration longer
Toxicity similar Teo et al.13
31.2 Gy/4 F (Includes
M)
5
32 Gy/16 F
bid
152 IIIA–IV KPS 50 8.4 38 Symptom control
equivalent; no
difference in tumor
response or PFS
Earlier esophagitis
w/16F; no severe
late reactions
Nestle et al.14
60 Gy/30 F (Includes
M)
8.3, p  0.76 36
40 Gy/10 F
split
240 Inoperable
III
KPS 50 8.3 28 Difference in survival;
symptom response
not assessed
Esophagitis and
pnuemonitis
equivalent; 2 pts
w/split course had
broncho-esophageal
fistula
Reinfuss et al.15
50 Gy/25 F
20–25 Gy/
4–5 F
12 48, p  0.05
40 Gy/10 F 409 Inoperable KPS 60 6.2 NR Symptom control
equivalent; no
difference in tumor
response
Worse pneumonitis
w/split course
Simpson et al.16
split
30 Gy/10 F 6.9, p  0.08
40 Gy/20 F
20 Gy/5 F 100 Inoperable WHO 1–4 5.3 11 Symptom control
equivalent
Toxicity similar Senkus-Konefka
et al.1716 Gy/2 F (Includes
M)
8, p  0.016 27
39 Gy/13 F 509 Inoperable WHO 0–2 9 36 2 F had more rapid
palliation; 13F w/
longer duration of
response
13 F w/worse
anorexia, nausea,
dysphagia;
myelopathy in
3 pts
MRC III18
17 Gy/2 F 7, p  0.003 31
45 Gy/15 F 84 III WHO 8.5 37 76% 15 F w/worse
dysphagia
Abratt et al.19
35 Gy/10 F 0–2 8.5 45 68%
22.5 Gy/5 F 216 Suitable for
palliation
Any NR 20 2 F better for chest
pain, cough
2 F w/worse
dysphagia
Rees et al.20
17 Gy/2 F 20
NS
a Median overall survival for patients completing entire course of radiation.
F, fractions; M, extrathoracic metastasis; KPS, Karnofsky performance status score; WHO, World Health Organization performance status score; NR, not reported; NS, not
significant.
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relative to the endpoints of symptom relief and OS while
acknowledging that symptom palliation may indeed be a
function of local tumor response. However, it is important to
assert that OS in our patients was not compromised and is
consistent with other reports in this patient population, de-
spite the break in treatment. Also, a considerable proportion
of our patients presented with poor prognostic factors, includ-
ing approximately 50% with stage IV disease, 61% with
weight loss, and 23% with Karnofsky performance status
score 60. Our argument for the split-course radiation is that
the 2-week break allows us to select patients who can sustain
the full course of palliative radiation to 50 Gy and above.
Stephens et al.23 proposed that the analysis of symptom
palliation should include a measure of stabilization and oc-
currence of new complaints because of the tumor or treat-
ment. Furthermore, the duration of palliative effect should be
scored objectively. The retrospective design of this study did
not allow for consistent assessment of the degree of improve-
ment, new complaints during RT, or duration of palliation.
Rather, we extracted data relevant to whether the symptoms
resolved during and after RT. Also, symptom palliation and
toxicities were mostly physician assessed, and it is well
known that clinicians tend to over- or underestimate patient’s
symptoms.24 Finally, the interpretation of our data is limited
by the method with which these endpoints were assessed—
91% were obtained from clinical notes.
Despite these limitations, we report that symptom pal-
liation using this regimen is promising and posed minimal
toxicities; therefore, we propose that these data may serve as
the basis for the design of future prospective studies evalu-
ating split-course palliative chest RT, with the incorporation
of validated symptom inventory tools and a formal quality of
life assessment.
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